Journal of diabetes and its complications最新文献

筛选
英文 中文
Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study 添加胰高血糖素样肽-1 受体激动剂对基础胰岛素治疗的 2 型糖尿病患者的糖尿病并发症和死亡率的影响:韩国真实世界研究。
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-26 DOI: 10.1016/j.jdiacomp.2025.108983
Kyoung Hwa Ha , Won Kim , Dong Han Kim , Dae Jung Kim
{"title":"Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study","authors":"Kyoung Hwa Ha ,&nbsp;Won Kim ,&nbsp;Dong Han Kim ,&nbsp;Dae Jung Kim","doi":"10.1016/j.jdiacomp.2025.108983","DOIUrl":"10.1016/j.jdiacomp.2025.108983","url":null,"abstract":"<div><h3>Aims</h3><div>To compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) on composite of diabetes-related complications and mortality with that of adding short-acting insulin (SAI) or shifting to premixed insulin among basal insulin (BI)-treated individuals with type 2 diabetes mellitus (T2DM) in South Korea.</div></div><div><h3>Methods</h3><div>From the Health Insurance Review and Assessment Service database, individuals with T2DM who initiated BI treatment and had advanced their treatment regimen from July 1, 2012, to December 31, 2018.</div></div><div><h3>Results</h3><div>A total of 38,634 individuals with T2DM were included in this study. Compared to adding SAI to BI, adding GLP-1RA was associated with decreased risks of cardiovascular complications (hazard ratio 0.56; 95 % confidence interval 0.43–0.72), severe microvascular complications (0.30; 0.19–0.48), diabetes-related hospitalization (0.62; 0.53–0.73), and all-cause mortality (0.27; 0.13–0.57). Compared to switching to premixed insulin, adding GLP-1RA was also associated with lower risk of cardiovascular complications (0.65; 0.51–0.84), severe microvascular complications (0.36; 0.22–0.58), diabetes-related hospitalization (0.62; 0.53–0.73), and all-cause mortality (0.32; 0.15–0.67).</div></div><div><h3>Conclusions</h3><div>In this real-world Korean study, adding GLP-1RA to BI reduced risks of diabetes complications and all-cause mortality than adding SAI or shifting to premixed insulin.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 108983"},"PeriodicalIF":2.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-25 DOI: 10.1016/j.jdiacomp.2025.108981
Ruoqi Liu , Zhuomin Qu , Yizhuo Feng , Lu Bai , Xueqian Liu , Xuemei Fan , Xiaoqi Liu , Lingxia Zhao
{"title":"Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i","authors":"Ruoqi Liu ,&nbsp;Zhuomin Qu ,&nbsp;Yizhuo Feng ,&nbsp;Lu Bai ,&nbsp;Xueqian Liu ,&nbsp;Xuemei Fan ,&nbsp;Xiaoqi Liu ,&nbsp;Lingxia Zhao","doi":"10.1016/j.jdiacomp.2025.108981","DOIUrl":"10.1016/j.jdiacomp.2025.108981","url":null,"abstract":"<div><h3>Background</h3><div>Currently, the prevalence of diabetes is rising. Patients with diabetes often face high risks of kidney disease, cardiovascular disease, and retinal disease. Cardiovascular complications are the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus. Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist. Research has shown that finerenone provides renal, cardiac, and retinal protection in patients with type 2 diabetes. Currently, various drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, sodium-glucose co-transporter 2 inhibitors) are effective in treating diabetic vascular complications, but each has its limitations. Combining finerenone with RAS Inhibitors/SGLT-2i may yield better clinical outcomes.</div></div><div><h3>Methods</h3><div>This review aggregates research on the mechanisms and clinical efficacy of finerenone, RAS Inhibitors, and SGLT-2i used individually, as well as in combination, for the treatment of vascular complications in diabetes from various databases.</div></div><div><h3>Results</h3><div>This review shows that combining finerenone with RAS inhibitors/ SGLT-2 inhibitors can further reduce proteinuria, the urinary albumin-to-creatinine ratio, and the risk of hyperkalemia, slow CKD progression, reduce atherosclerosis, myocardial fibrosis, and hypertrophy, and lower the incidence of atrial fibrillation, myocardial infarction, and heart failure. It can also reduce retinal neovascularization, macular edema, and inflammation. Overall, combining can further lower the risk of complications in type 2 diabetic patients.</div></div><div><h3>Conclusions</h3><div>In summary, combining finerenone with RAS inhibitors and SGLT-2i is a promising treatment strategy. However, the molecular mechanisms and interactions are not fully understood, necessitating more basic research and clinical trials to provide evidence. Combining finerenone with existing treatments may yield better clinical outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108981"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-21 DOI: 10.1016/j.jdiacomp.2025.108978
Wiebke van Beurden , Yuly P. Mendoza , Naomi F. Lange , Jaime Bosch , Annalisa Berzigotti , Susana G. Rodrigues
{"title":"FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists","authors":"Wiebke van Beurden ,&nbsp;Yuly P. Mendoza ,&nbsp;Naomi F. Lange ,&nbsp;Jaime Bosch ,&nbsp;Annalisa Berzigotti ,&nbsp;Susana G. Rodrigues","doi":"10.1016/j.jdiacomp.2025.108978","DOIUrl":"10.1016/j.jdiacomp.2025.108978","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Patients with compensated advanced chronic liver disease (cACLD) and treated type 2 diabetes have an increased risk for liver-related events, but data regarding this population is lacking, particularly, taking into account novel treatments. We assessed the role of Fibrosis-4 index and other variables to predict events.</div></div><div><h3>Methods</h3><div>First hepatic decompensation, liver transplantation (OLT), death, hepatocellular carcinoma (HCC) and bacterial infections over a follow-up period of 28.7 (16–49.4) months were retrospectively identified from 106 patients with treated type 2 diabetes and liver stiffness measurement &gt;10 kPa suggesting ACLD. We identified predictors of events using Cox regression. Additionally, we evaluated treatment effect with add-on GLP-1 receptor agonists (GLP-1-RA) compared to other antidiabetic medications.</div></div><div><h3>Results</h3><div>FIB-4 was associated with hepatic decompensation, OLT and death (HR 1.517, 95%CI 1.226–1.879, <em>p</em> ≤ 0.001), HCC (HR 1.369, 95%CI 1.046–1.791, <em>p</em> = 0.022) and bacterial infections (HR 1.379, 95%CI 1.118–1.702, <em>p</em> = 0.003). Propensity score adjusted analysis for GLP-1-RA treatment did not show an effect (HR 0.240, 95%CI 0.044–1.315, <em>p</em> = 0.1). Survival was worse in those with more advanced disease defined by FIB-4 &gt; 2.67 (<em>p</em> = 0.02).</div></div><div><h3>Conclusion</h3><div>FIB-4 is a strong prognostic tool to screen patients and refer them to specialists, in cACLD patients and pharmacologically treated type 2 diabetes, irrespective of treatment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108978"},"PeriodicalIF":2.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-19 DOI: 10.1016/j.jdiacomp.2025.108977
Kalpesh Patani , Amit Joharapurkar , Rajesh Sundar , Samadhan Kshirsagar , Sunil Metiya , Ashutosh Kumar , Mukul Jain
{"title":"Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models","authors":"Kalpesh Patani ,&nbsp;Amit Joharapurkar ,&nbsp;Rajesh Sundar ,&nbsp;Samadhan Kshirsagar ,&nbsp;Sunil Metiya ,&nbsp;Ashutosh Kumar ,&nbsp;Mukul Jain","doi":"10.1016/j.jdiacomp.2025.108977","DOIUrl":"10.1016/j.jdiacomp.2025.108977","url":null,"abstract":"<div><h3>Objectives</h3><div>Type 2 diabetes is caused due to inadequate glucose utilization in the liver and pancreas due to insulin resistance. Glucokinase enzyme plays a key role in metabolism of glucose and insulin release and hence glucokinase activation can be a useful therapeutic target for treatment of type 2 diabetes.</div></div><div><h3>Methods</h3><div>Present study was conducted to investigate the effect of a novel glucokinase activator ZYGK1 in the preclinical models of diabetes in mice. The activity of ZYGK1 was evaluated using recombinant glucokinase, and isolated islets and hepatocytes. Acute effect on glucose disposal was evaluated in C57 mice and repeated dose effect was assessed in db/db mice, along with the evaluation in sulfonylurea-resistance db/db mice.</div></div><div><h3>Results</h3><div>ZYGK1 has potent glucokinase stimulating activity with EC50 of 43 nM and increased glucokinase activity in islets and hepatocytes in a dose-related manner. Oral administration of ZYGK1 (0.1 to 10 mg/kg) showed dose dependently improved glucose disposal and glucose dependent insulin secretion in oral glucose tolerance test (OGTT) in C57 mice. Repeated dose administration of ZYGK1 improved glucose homeostasis and nondiabetic as well as diabetic mice and sulfonylurea-resistant db/db mice.</div></div><div><h3>Conclusion</h3><div>ZYGK1 appears to be a potential therapeutic option for the treatment of type 2 diabetes owing to its action in the liver and pancreas, and in conditions resistant to sulfonylurea therapy.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108977"},"PeriodicalIF":2.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-19 DOI: 10.1016/j.jdiacomp.2025.108975
Qian Xu , Xuan Qiu , Hailing Di , Zhongkang Li , Zanchao Liu , Kuanzhi Liu
{"title":"Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway","authors":"Qian Xu ,&nbsp;Xuan Qiu ,&nbsp;Hailing Di ,&nbsp;Zhongkang Li ,&nbsp;Zanchao Liu ,&nbsp;Kuanzhi Liu","doi":"10.1016/j.jdiacomp.2025.108975","DOIUrl":"10.1016/j.jdiacomp.2025.108975","url":null,"abstract":"<div><h3>Objective</h3><div>Beyond its established glucose-lowering and weight-reducing benefits, glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as liraglutide may also mitigate sarcopenia. This study investigates the effects of liraglutide on diabetic sarcopenia and its underlying mechanisms.</div></div><div><h3>Methods</h3><div>A type 2 diabetic SD rat model was induced using a high-fat, high-sugar diet supplemented with a low dose of streptozotocin. Comparisons were made among control (Con), diabetic (DM), and liraglutide-treated (Li) groups for gastrocnemius muscle wet weight and length, histology (HE staining), immunofluorescence for muscle fiber typing, and Western blotting for aging-related proteins and YAP/TAZ pathway components. Concurrently, C2C12 myoblasts were differentiated into myotubes, treated with 60 mM glucose to model diabetic conditions, and assessed for morphological changes, senescence (SA-β-gal staining), and protein expression dynamics.</div></div><div><h3>Results</h3><div>Diabetic rats displayed significant reductions in muscle mass, length, and cross-sectional area, along with disorganized fiber architecture, all of which were improved by liraglutide. In vitro, C2C12 myotubes showed accelerated aging and atrophy under high-glucose conditions, which were significantly reduced by liraglutide. Analysis revealed increased expression of aging markers P53 and P21 and decreased YAP/TAZ/TEAD and Cyclin D1 levels in diabetic conditions, which were reversed following liraglutide treatment. The inhibition of YAP significantly negated the protective effects of liraglutide.</div></div><div><h3>Conclusion</h3><div>High glucose promotes muscle cell aging and sarcopenia, processes that liraglutide can attenuate by modulating the YAP/TAZ signaling pathway. This study underscores liraglutide's potential to alleviate muscle degeneration in diabetic sarcopenia through its regulatory impact on critical aging pathways.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108975"},"PeriodicalIF":2.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral edaravone ameliorates myocardial fibrosis in type 2 diabetic rats by TGF-β1/Smad signaling pathway
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-19 DOI: 10.1016/j.jdiacomp.2025.108976
Xiao-Yan Zhang , Yong-xuan Xu , Si-Quan Xue , Yue-Qin Zeng , Juan-Hua Gu , Xin-Fu Zhou , Hai-Yun Luo , Li-Jin Pu
{"title":"Oral edaravone ameliorates myocardial fibrosis in type 2 diabetic rats by TGF-β1/Smad signaling pathway","authors":"Xiao-Yan Zhang ,&nbsp;Yong-xuan Xu ,&nbsp;Si-Quan Xue ,&nbsp;Yue-Qin Zeng ,&nbsp;Juan-Hua Gu ,&nbsp;Xin-Fu Zhou ,&nbsp;Hai-Yun Luo ,&nbsp;Li-Jin Pu","doi":"10.1016/j.jdiacomp.2025.108976","DOIUrl":"10.1016/j.jdiacomp.2025.108976","url":null,"abstract":"<div><div>Myocardial fibrosis, characterized by increased reactive oxygen species (ROS), is a key pathological feature of diabetic cardiomyopathy (DCM). Although oral edaravone (EDA) shows therapeutic potential in ameliorating myocardial fibrosis in DCM, the precise mechanisms remain unclear. Transcriptome analysis of myocardial tissues revealed a dramatic up-regulation of the TGF-β1/Smad pathway, which was reversed by oral EDA treatment. In vitro studies showed that oral EDA attenuated myocardial fibrosis by inhibiting the TGF-β1/Smad signaling pathway and its downstream fibrosis key factors, Col3a1 and α-SMA. These findings suggest that oral EDA improves myocardial fibrosis in Type 2 diabetes mellitus (T2DM) by inhibiting the TGF-β1/Smad signaling pathway and holds promise as an effective treatment for myocardial fibrosis in DCM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108976"},"PeriodicalIF":2.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlighting the complex relationship between diabetes, renal function and bone health
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-19 DOI: 10.1016/j.jdiacomp.2025.108974
Joseph C. Lee , Jia Wen Chong , Shanal Kumar
{"title":"Highlighting the complex relationship between diabetes, renal function and bone health","authors":"Joseph C. Lee ,&nbsp;Jia Wen Chong ,&nbsp;Shanal Kumar","doi":"10.1016/j.jdiacomp.2025.108974","DOIUrl":"10.1016/j.jdiacomp.2025.108974","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108974"},"PeriodicalIF":2.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers - A literature review
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-13 DOI: 10.1016/j.jdiacomp.2025.108973
Ken Mackay, Rhiannon Thompson, Matthew Parker, James Pedersen, Hayden Kelly, Mairi Loynd, Emily Giffen, Angus Baker
{"title":"The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers - A literature review","authors":"Ken Mackay,&nbsp;Rhiannon Thompson,&nbsp;Matthew Parker,&nbsp;James Pedersen,&nbsp;Hayden Kelly,&nbsp;Mairi Loynd,&nbsp;Emily Giffen,&nbsp;Angus Baker","doi":"10.1016/j.jdiacomp.2025.108973","DOIUrl":"10.1016/j.jdiacomp.2025.108973","url":null,"abstract":"<div><div>Diabetic Foot Ulcers (DFUs) are chronic foot wounds, in a person with diabetes, which are associated with peripheral arterial insufficiency and/or peripheral neuropathy of the lower limb. Recent UK audit figures report that approximately 50–60 % of DFUs remain unhealed after 12 weeks. Previous research has suggested that ischaemia plays a key role in the pathophysiology of many chronic wounds, including DFUs. For this reason, hyperbaric oxygen therapy (HOT) has been investigated. The study aimed to investigate 1) Current understanding of the physiology of normal wound healing and the pathological mechanisms that occur in DFUs to interrupt these processes; 2) Effectiveness of current DFU treatment approaches; 3) Effectiveness from clinical trials and meta-analyses for any demonstrated therapeutic benefits of HOT in the treatment of DFUs, 4) Patient selection criteria for HOT, and patients who stand to benefit most from treatment.</div><div>The review found that wound healing is a complex process, involving many cells and signalling molecules, and it remains incompletely understood. However, current evidence suggests that hyperglycaemia, hypoxia, chronic inflammation (due to infection, immune-cell dysfunction or other causes), peripheral neuropathy, and macro- and micro-vascular dysfunction may all adversely affect DFU healing. The review found that current NICE guidelines do not approve HOT therapy in the UK for DFU's, despite encouraging clinical research findings. HOT shows theoretical promise and has been successfully used in the treatment of individual DFUs for several decades. Despite this, there remains a lack of strong clinical evidence of benefits to encourage HOT's wider use. The review found that there were four important patient selection criteria for HOT treatment, including glycaemic control, possible contraindications and complications associated with treatment, ulcer severity and resistance to first and second line treatments. The review concluded that further high-quality clinical research is needed to improve the evidence base.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108973"},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of evidence-based foot screening in people with diabetes: A scoping review
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-12 DOI: 10.1016/j.jdiacomp.2025.108972
Jemma M. Houghton , Matthew C. Hynes , Nia W. Roberts , Helene-Mari van der Westhuizen , Joel A. Dave , Andrew Farmer
{"title":"Implementation of evidence-based foot screening in people with diabetes: A scoping review","authors":"Jemma M. Houghton ,&nbsp;Matthew C. Hynes ,&nbsp;Nia W. Roberts ,&nbsp;Helene-Mari van der Westhuizen ,&nbsp;Joel A. Dave ,&nbsp;Andrew Farmer","doi":"10.1016/j.jdiacomp.2025.108972","DOIUrl":"10.1016/j.jdiacomp.2025.108972","url":null,"abstract":"<div><h3>Background</h3><div>Recommendations to prevent diabetes ulceration and amputation include an annual foot check, primarily screening for sensation and circulation. Using these simple, evidence-based components is vital to identifying complications early, assessing risk, and managing care to prevent or delay amputations. However, routine implementation of these assessments is suboptimal and approaches to their integration remain poorly understood.</div></div><div><h3>Aim</h3><div>We aimed to identify and synthesize information on the factors affecting implementation of simple evidence-based diabetes foot screening.</div></div><div><h3>Methods</h3><div>We reviewed published and grey literature using a blinded two-stage process by two independent reviewers. Included studies were primary research that implemented or improved foot screening for adults with type 1 or 2 diabetes, assessing at least one of the following: 10-<em>g</em> monofilament sensitivity, pedal pulse palpation, or history of ulceration or amputation. A thematic synthesis approach was used.</div></div><div><h3>Results</h3><div>We screened 5133 titles and abstracts, reviewed 102 full-text articles, and included 26 studies in the final analysis. We identified four key themes: (1) Existing diabetes screening (i.e. retinal screening) or treatment interventions (i.e. medication collection) provide opportunities for synergistic integration; (2) Annual event-based foot screening (e.g. on World Diabetes Day) in lower resource settings provides community-focused preventative care; (3) Further opportunities to increase access to foot screening include self-administered screening and screening in complex residential settings; (4) Healthcare provider champions are essential for local foot screening implementation in primary and secondary care.</div></div><div><h3>Conclusion</h3><div>Further research should evaluate the issues identified in these four themes, in different contexts, and with support of implementation frameworks.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108972"},"PeriodicalIF":2.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease 磁共振波谱分析2型糖尿病合并慢性肾病患者的肾脏脂肪。
IF 2.9 3区 医学
Journal of diabetes and its complications Pub Date : 2025-02-01 DOI: 10.1016/j.jdiacomp.2024.108923
Niels Sondergaard Heinrich , Rune Ploegstra Pedersen , Mark Bitsch Vestergaard , Ulrich Lindberg , Ulrik Bjørn Andersen , Bryan Haddock , Alessia Fornoni , Henrik Bo Wiberg Larsson , Peter Rossing , Tine Willum Hansen
{"title":"Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease","authors":"Niels Sondergaard Heinrich ,&nbsp;Rune Ploegstra Pedersen ,&nbsp;Mark Bitsch Vestergaard ,&nbsp;Ulrich Lindberg ,&nbsp;Ulrik Bjørn Andersen ,&nbsp;Bryan Haddock ,&nbsp;Alessia Fornoni ,&nbsp;Henrik Bo Wiberg Larsson ,&nbsp;Peter Rossing ,&nbsp;Tine Willum Hansen","doi":"10.1016/j.jdiacomp.2024.108923","DOIUrl":"10.1016/j.jdiacomp.2024.108923","url":null,"abstract":"<div><h3>Background and hypothesis</h3><div>The kidneys may be susceptible to ectopic fat and its lipotoxic effects, disposing them to chronic kidney disease (CKD) in type 2 diabetes (T2D). We investigated whether the kidney parenchyma fat content and kidney sinus fat volume would be higher in persons with T2D and CKD.</div></div><div><h3>Methods</h3><div>Cross-sectional study including 29 controls, 27 persons with T2D and no CKD, and 48 persons with T2D and early CKD (urine albumin creatinine ratio (UACR) ≥ 30 mg/g). Kidney parenchyma fat content and kidney sinus fat volume were assessed using magnetic resonance spectroscopy and Dixon scans respectively.</div></div><div><h3>Results</h3><div>In the control, T2D without CKD and T2D with CKD groups, respectively, median [1st – 3rd quartile] UACR was 5 [4 – 6], 6 [5 – 10] and 95 [43 – 278] mg/g. and mean ± standard deviation estimated glomerular filtration rate was 89 ± 11, 94 ± 11 and 77 ± 22 ml/min/1.73m<sup>2</sup>. Kidney parenchyma fat content was, respectively, 1.0 [0.5–2.4], 0.7 [0.2–1.2], 1.0 [0.3–2.0] % (<em>p</em> = 0.26). Kidney sinus fat volume was 2.8 [1.6–7.6], 8.0 [4.7–11.3], 10.3 [5.7–14.0] ml (<em>p</em> &lt; 0.01). Around 90 % of T2D participants received a sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist.</div></div><div><h3>Conclusions</h3><div>In a setting of modern, multifactorial T2D management, kidney parenchyma fat content, evaluated with magnetic resonance spectroscopy, was similar among healthy controls and persons with T2D irrespective of CKD status. Still, kidney sinus fat volume was higher in the presence of T2D and higher still with CKD.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108923"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信